NCT06021678View on ClinicalTrials.gov

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
CD20-positive Non-Hodgkin Lymphoma
Interventions
DRUG

EX103 injection

Administered as specified in the treatment arm.

Trial Locations (4)

200233

RECRUITING

Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai

250012

RECRUITING

Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan

300020

RECRUITING

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin

450000

RECRUITING

Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Guangzhou Excelmab Inc.

INDUSTRY